Search For Additional Tests

Search Form
     
FACTOR 9 ACTIVITY
Number 266
CPT Code 85250
Alias FACTOR IX ACTIVITY, ANTIHEMOPHILIC FACTOR B
Specimen Container Blue Top Citrate
Specimen Type Plasma Citrate
Turn Around Time 
Days Performed 
Reference Range 
Alternate Specimen 
Volume 2 mL Plasma
Stability Ambient N/A
Stability Refrigerated N/A
Stability Frozen Preferred
Patient Preparation 

Ideally, the patient should not be on anticoagulant therapy. Avoid warfarin (Coumadin) therapy for two weeks prior to the test and heparin, direct Xa, and thrombin inhibitor therapies for about three days prior to testing.

Methodology 

Factor IX activity is determined using an aPTT-based one-stage clotting time assay.

Limitations 

Direct Xa or thrombin inhibitor therapy may cause factitiously low results.

Rejection Criteria 

Severe hemolysis; improper labeling; clotted specimen; specimen diluted with IV fluids; samples thawed in transit; improper sample type; sample out of stability

Additional Instructions 
Performing Laboratory Reference Laboratory
TagsFIX, FACTOR 9, F9

COVID-19 Testing Guidance

Primex Clinical Laboratories strives to provide clients with quality testing services to better support patient health. With the ongoing pandemic, COVID-19 testing has become high in demand yet testing supplies are limited.

Read More

COVID-19 Testing Guidance

Primex Clinical Laboratories strives to provide clients with quality testing services to better support patient health. With the ongoing pandemic, COVID-19 testing has become high in demand yet testing supplies are limited.

Read More